Evidence organized by emotional and functional themes
Reviewed studies document emotional, mechanistic, functional, and predictive effects across stimulant and atomoxetine treatments, organized into four thematic domains.
Evidence Map
Tabbed synthesis of the reviewed studies
Emotional dysregulation outcomes
- Reimherr et al. (2005): In adults, roughly one in three participants showed emotional dysregulation at baseline, and atomoxetine outperformed placebo on WRAADDS domains including affective lability, temper, and emotional overreactivity.
- Marchant et al. (2011): Long-term atomoxetine treatment was associated with sustained emotional gains, with stronger responses in women and in participants who entered treatment with higher baseline emotional dysregulation.
Mechanistic effects on emotional processing
- Griffiths et al. (2018), ACTION RCT: Atomoxetine in youth improved response inhibition and emotional cognition, suggesting that treatment effects extend into the processing systems that shape emotional self-regulation.
- Posner et al. (2011), fMRI study: Stimulant treatment in adolescents reduced amygdala hyperactivation to emotional stimuli and normalized fronto-limbic activity, pointing to a plausible neurobiologic route for improved emotion regulation.
Functional capacity and quality of life
- De Bruyckere et al. (2016): Atomoxetine in children improved daily functioning over 10 to 24 weeks, with outcomes tracked using BRIEF-A, Sheehan Disability Scale, AAQoL, and SF-36 instruments.
- Banaschewski et al. (2013), randomized trial: Lisdexamfetamine improved WFIRS-P and CHIP-CE scores in pediatric patients, with gains reported in schoolwork, home life, and friendships.
- Folkins et al. (2025): Stimulant treatment was associated with higher grades, better attendance, higher graduation rates, and more post-secondary transitions compared with untreated ADHD.
Comparative and predictive findings
- 202 et al. (2023): Methylphenidate and atomoxetine both improved behavior and emotion, while methylphenidate showed stronger effects on hyperactivity and delinquency.
- Ozbaran et al. (2023): Emotional non-acceptance was associated with switching toward atomoxetine, whereas alexithymia was associated with staying on methylphenidate, suggesting that emotional style may predict treatment pathways.
| Study | Treatment | Population | Key Outcome | Result |
|---|---|---|---|---|
| Reimherr et al. (2005) | Atomoxetine vs placebo | Adults with ADHD | WRAADDS emotional domains | Atomoxetine improved affective lability, temper, and emotional overreactivity. |
| Marchant et al. (2011) | Long-term atomoxetine | Adults with ADHD | Durability of emotional improvement | Sustained gains, especially in women and those with higher baseline ED. |
| Griffiths et al. (2018) | Atomoxetine | Youth with ADHD | Response inhibition and emotional cognition | Improved inhibitory control and emotion-related cognition. |
| Posner et al. (2011) | Stimulants | Adolescents with ADHD | Emotional fMRI processing | Reduced amygdala hyperactivation and normalized fronto-limbic function. |
| De Bruyckere et al. (2016) | Atomoxetine | Children with ADHD | Daily functioning and QoL | Functional gains across 10 to 24 weeks on multiple disability and QoL instruments. |
| Banaschewski et al. (2013) | Lisdexamfetamine | Pediatric ADHD | WFIRS-P and CHIP-CE | Improved schoolwork, home life, and friendship-related function. |
| Folkins et al. (2025) | Stimulants | Youth with ADHD | Academic outcomes | Higher grades, attendance, graduation, and post-secondary transition rates versus untreated ADHD. |
| 202 et al. (2023) | Methylphenidate vs atomoxetine | ADHD cohort | Behavior and emotion | Both improved outcomes; methylphenidate showed stronger effects on hyperactivity and delinquency. |
| Ozbaran et al. (2023) | Medication switching patterns | ADHD cohort | Predictive emotional profile | Emotional non-acceptance predicted switching to atomoxetine; alexithymia predicted staying on methylphenidate. |